Changing how immune cells read their genes to help transplants last
Modulation of chromatin dynamics to promote transplant survival
Researchers are exploring whether shifting how T cells' DNA packaging is read can reduce rejection and help organ transplant recipients keep their grafts longer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Methodist Hospital Research Institute NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11226575 on NIH RePORTER |
What this research studies
This project focuses on a protein called BRD4 that helps control gene switches in aggressive T cells that drive transplant rejection. Scientists use genetically modified mice lacking BRD4 in T cells and lab methods that map DNA accessibility and 3D chromatin structure (like ATAC‑seq) to see how 'super enhancers' create a rejection-prone cell fate. By defining these chromatin 'switches' they aim to identify ways to quiet harmful T cells and promote long-term graft acceptance. If the work moves toward humans, patients may be asked to donate blood or tissue samples or to join clinical testing at the research center.
Who could benefit from this research
Good fit: Ideal candidates would be people who have received or are awaiting organ transplants and who are willing to provide samples or participate in future clinical testing.
Not a fit: Patients whose transplant problems are due to surgical complications, infections, or non-immune causes are unlikely to benefit from this immune-focused approach.
Why it matters
Potential benefit: If successful, this work could lead to treatments that silence rejection-causing T cells and help transplanted organs survive longer.
How similar studies have performed: Drugs targeting BRD4 and related chromatin readers have changed immune responses in animal and early-phase studies, but they are not yet proven to prevent organ rejection in patients.
Where this research is happening
Houston, United States
- Methodist Hospital Research Institute — Houston, United States (Active)
Researchers
- Principal investigator: Li, Xian Chang — Methodist Hospital Research Institute
- Study coordinator: Li, Xian Chang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.